financetom
Business
financetom
/
Business
/
Kits Eyecare Q3 Earnings Miss Expectations, But Revs Beat; Also Flags Revs Beat In Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kits Eyecare Q3 Earnings Miss Expectations, But Revs Beat; Also Flags Revs Beat In Q4
Nov 6, 2024 6:12 AM

08:34 AM EST, 11/06/2024 (MT Newswires) -- Kits Eyecare ( KTYCF ) reported Wednesday a slight earnings miss for the third quarter, even as revenues beat expectations, and the company flagged higher than expected revenues for the fourth quarter.

The company recorded third quarter net earnings of $0.132 million, or $0.00 per share, down from near $0.5 million, or $0.02 basic and $0.01 diluted a year earlier. It missed a consensus mean of $0.01 EPS GAAP at Capital IQ.

Revenue for the quarter ended Sept. 30 was $41.9 million, up 34.3% from $31.2 million a year earlier; analysts surveyed by Capital IQ had projected $41.7 million.

For the fourth quarter, Kits Eyecare ( KTYCF ) expects revenue between $43 million and $45 million, with adjusted EBITDA margins anticipated to be between 3% and 5%. The consensus forecast for Q4 at Capital IQ was $40.60 million.

Kits Eyecare ( KTYCF ) shares closed at $10 on Monday, up 0.20%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Altair Nearing Deal to be Acquired by Siemens
Market Chatter: Altair Nearing Deal to be Acquired by Siemens
Nov 3, 2024
02:44 PM EDT, 10/29/2024 (MT Newswires) -- Altair Engineering ( ALTR ) shares were up more than 8% Tuesday afternoon after Bloomberg reported that German automation equipment company Siemens is close to a deal to acquire the software firm. The deal, which would be Siemens' largest transaction ever, could be announced as soon as Wednesday, people familiar with the matter...
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Nov 3, 2024
On Tuesday, Coya Therapeutics, Inc. ( COYA ) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24). The study met its primary and secondary endpoints, demonstrating that treatment with low-dose interleukin-2 is safe and well-tolerated in patients...
Boeing Faces Overcharging Allegations Over US Air Force's C-17 Spare Parts Purchases
Boeing Faces Overcharging Allegations Over US Air Force's C-17 Spare Parts Purchases
Nov 3, 2024
02:27 PM EDT, 10/29/2024 (MT Newswires) -- Boeing ( BA ) is facing overcharging allegations following an audit by the Department of Defense Office of Inspector General regarding nearly $1 million worth of C-17 aircraft spare parts purchased by the US Air Force. The agency said Tuesday the Air Force overpaid for a dozen different types of spare parts on...
Investor gets prison time for fake $4 billion Getty Images takeover bid
Investor gets prison time for fake $4 billion Getty Images takeover bid
Nov 3, 2024
BOSTON (Reuters) - A former CEO of several publicly traded companies was sentenced on Tuesday to 10 months in prison after admitting he launched a fake $4 billion takeover bid for Getty Images Holdings ( GETY ) to artificially inflate the visual media company's stock price. Scott Murray, who previously served as chief executive of Stream Global Services and 3Com,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved